TSC-101 Cohort C: 11/14 patients achieved complete donor chimerism; Phase 3 start planned this month

TScan Therapeutics, Inc.

11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion; 2 additional patients approaching.
~90% manufacturing success rate (17/19) with commercial-ready process; 14/19 patients received first infusion.
One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT.
TSC-101 well-tolerated; safety consistent with Cohort A; company plans to initiate Phase 3 ALLOHA-2 study this month.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.